Abstract Number: 700 • 2018 ACR/ARHP Annual Meeting
Immunogenicity of Originator and Biosimilar Infliximab: Anti-Drug Antibody Occurence, Cross-Reactivity and Epitope Specificities across Six Diseases. Analyses from a Norwegian Randomized Switching Trial
Background/Purpose: The NOR-SWITCH study was funded by the Norwegian government to investigate switching from originator infliximab (INX) to biosimilar CT-P13, in spondyloarthritis (SpA), rheumatoid arthritis…Abstract Number: 701 • 2018 ACR/ARHP Annual Meeting
Network Meta-Analysis of Targeted Immunomodulators in the Treatment of Psoriatic Arthritis Patients without Prior Biologic Treatment
Background/Purpose: With multiple targeted immunomodulators (TIMs) approved by the FDA for the treatment of psoriatic arthritis (PsA), the relative efficacy and cost-effectiveness of these TIMs…Abstract Number: 702 • 2018 ACR/ARHP Annual Meeting
Effect of Biologics on Radiographic Progression of Peripheral Joints in Patients with Psoriatic Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Background/Purpose: Psoriatic arthritis (PsA) often leads to structural damage with resultant disability and reduced quality of life. Biologic disease modifying anti-rheumatic drugs (bDMARDs), including tumor…Abstract Number: 703 • 2018 ACR/ARHP Annual Meeting
Articular Manifestations in Patients with Inflammatory Bowel Disease Treated with Vedolizumab
Background/Purpose: Vedolizumab is a humanised IgG1 monoclonal antibody anti-α4β7 integrin agent used in inflammatory bowel disease (IBD). It modulates gut inflammation by preventing leukocyte migration…Abstract Number: 704 • 2018 ACR/ARHP Annual Meeting
Metabolomics Analysis of Insulin Resistance in Mild/Inactive Non-Diabetic Systemic Lupus Erythematosus Women
Background/Purpose: SLE patients present a higher prevalence of insulin resistance (IR) and metabolic syndrome (MetS) than age- and sex-matched healthy controls. Advances in technology are…Abstract Number: 705 • 2018 ACR/ARHP Annual Meeting
Prevalence of Cervical Human Papillomavirus Infection in Women with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
Background/Purpose: Human papillomavirus (HPV), a common sexually-transmitted infection, is considered a necessary cause of cervical cancer. The objectives of this systematic review and meta-regression were:…Abstract Number: 706 • 2018 ACR/ARHP Annual Meeting
Increased Incidence and Prevalance of Resistant Hypertension in Patients with Systemic Lupus Erythematosus: A Retrospective Cohort Study
Background/Purpose: Resistant hypertension (RHTN) is associated with increased risk of cardiovascular events in the general population. Patients with systemic lupus erythematous (SLE) have increased cardiovascular…Abstract Number: 707 • 2018 ACR/ARHP Annual Meeting
Subclinical Parameters of Arterial Stiffness and Arteriosclerosis Correlate with QRISK3 in Systemic Lupus Erythematosus
Background/Purpose: It is well known that cardiovascular diseases (CVD) are a major contributor of death in systemic lupus erythematosus (SLE) as well in other rheumatic…Abstract Number: 708 • 2018 ACR/ARHP Annual Meeting
The Montreal Cognitive Assessment Test. a Useful Tool in Screening of Cognitive Impairment in Patients with Systemic Lupus Erythematosusshort Title: Cognitive Impairment in SLE
Background/Purpose: Systemic lupus erythematosus (SLE) is an inflammatory, chronic and multisystemic disease, which can be related with a long range of neuropsychiatric manifestations, including cognitive…Abstract Number: 709 • 2018 ACR/ARHP Annual Meeting
Differential Characteristics of Lupus Psychosis and Steroid Psychosis
Background/Purpose: Psychiatric manifestations are relatively common in patients with systemic lupus erythematosus (SLE). Since there are a number of factors causing psychiatric manifestations other than…Abstract Number: 710 • 2018 ACR/ARHP Annual Meeting
An Analysis of Cell-of-Origin in Diffuse Large B-Cell Lymphoma in Systemic Lupus Erythematosus, Including Molecular and Clinical Factors Associated with Survival
Background/Purpose: Systemic lupus erythematosus (SLE) is associated with increased risk of diffuse large B-cell lymphoma (DLBCL). DLBCL is routinely classified by cell-of-origin (COO), with non-germinal…Abstract Number: 711 • 2018 ACR/ARHP Annual Meeting
Recurrence of Lupus Nephritis in Renal Transplant Recipients
Background/Purpose: Recurrence of lupus nephritis in the graft is a concern in lupus patients with end stage renal disease who undergo renal transplantation. The recurrence…Abstract Number: 712 • 2018 ACR/ARHP Annual Meeting
Higher Prednisolone Dose during Treatment of Tuberculosis Correlates with Mortality during Tuberculosis Treatment in Systemic Lupus Erythematosus Patients: A Retrospective Cohort Study
Background/Purpose: Tuberculosis (TB) has complex interplay with systemic lupus erythematosus (SLE). In addition, SLE, corticosteroid, and immunosuppressants are associated with TB infection. However, the prognostic…Abstract Number: 713 • 2018 ACR/ARHP Annual Meeting
Soluble ST2 and CXCL-10 May Serve As Biomarkers of Diastolic Dysfunction in SLE and Correlate with Disease Activity and Damage
Background/Purpose: Subclinical myocardial dysfunction has been reported to occur earlyin SLE. The pathogenesis and prognosis of this finding is not clear. The study aims to…Abstract Number: 714 • 2018 ACR/ARHP Annual Meeting
A Predictive Clinical-Immunological Index for Infections Unveils Novel Innate and Adaptive Immunity Abnormalities As Key Risk Factors for Infections in a Cohort of Patients with Systemic Lupus Erythematosus
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have multiple innate and adaptive immune response abnormalities. It is unknown whether they play a key role in…
ACR Meeting Abstracts